Oncopeptide I recall they tried the drug on one of their trials on earlier stages of cancer so at the end their safety or lack of it got them into problems now this is a good thing to consider during dose escalation process for THTX so their RP2D is safe.
“The agency in July alerted patients and healthcare professionals that the confirmatory trial was halted as the combination of Pepaxto and dexamethasone showed an increased risk of death when compared to placebo.
The hazard ratio (HR) for overall survival (OS) of the melphalan flufenamide containing investigational arm compared to the control arm of pomalidomide was 1.104 (95% CI: 0.846,1.441),” the agency said.”
Endpoints News